Monopar Therapeutics Inc
MNPR57.750USD
+0.870+1.53%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
384.78MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Monopar Therapeutics Inc Unternehmen
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc Informationen
BörsenkürzelMNPR
Name des UnternehmensMonopar Therapeutics Inc
IPO-datumDec 19, 2019
CEORobinson (Chandler D)
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeDec 19
Addresse1000 Skokie Blvd Ste 350
StadtWILMETTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl60091-1146
Telefon18473880349
Websitehttps://www.monopartx.com/
BörsenkürzelMNPR
IPO-datumDec 19, 2019
CEORobinson (Chandler D)
Führungskräfte von Monopar Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Mon, Feb 2
Aktualisiert: Mon, Feb 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Andere
48.28%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Andere
48.28%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
28.96%
Hedge Fund
19.01%
Corporation
14.94%
Investment Advisor
10.84%
Venture Capital
9.00%
Individual Investor
6.75%
Research Firm
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Andere
10.12%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
123
4.56M
68.20%
+926.42K
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
1.29M
19.26%
+115.00K
+9.81%
Sep 30, 2025
Adage Capital Management, L.P.
659.20K
9.86%
+60.00K
+10.01%
Sep 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.14%
--
--
Apr 04, 2025
RA Capital Management, LP
511.21K
7.65%
--
--
Sep 30, 2025
AstraZeneca PLC
387.33K
5.8%
+387.33K
--
Oct 23, 2024
The Vanguard Group, Inc.
208.22K
3.12%
+121.73K
+140.75%
Sep 30, 2025
Wellington Management Company, LLP
231.46K
3.46%
+231.46K
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
182.63K
2.73%
-1.34K
-0.73%
Sep 30, 2025
Deerfield Management Company, L.P.
159.76K
2.39%
+159.76K
--
Sep 30, 2025
Saturn V Capital Management LP
155.37K
2.33%
+155.37K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.05%
Vanguard US Momentum Factor ETF
Anteil0.04%
iShares Russell 2000 Growth ETF
Anteil0.02%
Proshares Ultra Russell 2000
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
